Targeting ERLIN1 reveals a coordinated cholesterol-dependent vulnerability in hepatocellular carcinoma

Key Points

• The research aims to explore ERLIN1 as a druggable target for treatment in cholesterol-dysregulated hepatocellular carcinoma.
• Investigated the role of ERLIN1 in HCC
• Examined the effects of ASB11-ERLIN1 targeting
• Utilized ZoA, a clinically approved drug
• Assessed cholesterol levels in treated models
• Targeting ERLIN1 effectively restored cholesterol homeostasis
• Demonstrated potential to overcome limitations of existing therapies
• Highlighted ERLIN1 as a critical metabolic vulnerability in HCC